Septerna, Inc. (NASDAQ:SEPN - Get Free Report) CFO Gil Labrucherie sold 20,000 shares of Septerna stock in a transaction on Monday, November 16th. The shares were sold at an average price of $41.62, for a total value of $832,400.00. Following the sale, the chief financial officer directly owned 20,000 shares of the company's stock, valued at $832,400. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Septerna Stock Performance
Septerna stock traded down $0.57 during midday trading on Wednesday, hitting $39.45. 298,919 shares of the company's stock were exchanged, compared to its average volume of 418,598. The company has a market cap of $1.88 billion, a P/E ratio of -30.58 and a beta of 2.20. The stock has a 50-day moving average price of $40.64 and a two-hundred day moving average price of $33.37. Septerna, Inc. has a 52-week low of $21.63 and a 52-week high of $53.34.
Septerna (NASDAQ:SEPN - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The business had revenue of $18.88 million during the quarter, compared to analysts' expectations of $20.78 million. As a group, sell-side analysts expect that Septerna, Inc. will post -1.51 earnings per share for the current year.
Institutional Investors Weigh In On Septerna
A number of institutional investors have recently made changes to their positions in SEPN. Renaissance Technologies LLC purchased a new position in Septerna in the 1st quarter worth approximately $906,000. TRV GP V LLC purchased a new stake in shares of Septerna during the second quarter valued at approximately $208,160,143. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Septerna during the second quarter valued at approximately $445,000. First Light Asset Management LLC boosted its stake in shares of Septerna by 31.4% during the second quarter. First Light Asset Management LLC now owns 963,260 shares of the company's stock valued at $32,260,000 after purchasing an additional 230,400 shares during the period. Finally, TRV GP VI LLC bought a new position in shares of Septerna in the second quarter worth approximately $141,048,460.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Wall Street Zen lowered shares of Septerna from a "hold" rating to a "sell" rating in a research report on Saturday. Stifel Nicolaus increased their price target on shares of Septerna from $49.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, November 10th. JonesTrading raised their price objective on shares of Septerna from $43.00 to $62.00 and gave the company a "buy" rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. lifted their price objective on shares of Septerna from $38.00 to $48.00 and gave the stock an "overweight" rating in a report on Wednesday, August 19th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and set a $49.00 price objective on shares of Septerna in a report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Septerna currently has a consensus rating of "Moderate Buy" and an average target price of $56.44.
View Our Latest Stock Analysis on SEPN
Septerna Company Profile
(
Get Free Report)
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Septerna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Septerna wasn't on the list.
While Septerna currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.